← IndicationsOpen filtered programs
Landscape
Autoimmune Inner Ear Disease
Autoimmune Inner Ear Disease has 2 tracked records across 2 named organizations, including 0 strong-evidence records and 0 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.
2
Pipeline Records
strong evidence + caveats + candidates
0
Strong Evidence
2 checked records with caveats
0
Active Programs
currently active
0
Marketed / Approved
commercial or approved
2
Organizations
companies, sponsors, and institutions
Competitive Density
6/100
organization breadth + program volume
Pipeline Velocity
0/100
active and late-stage share
Evidence Coverage
0/100
share strong evidence
Completion Signal
0/100
late-stage, approved, or marketed
Attrition Rate
50/100
share discontinued
Concentration
50/100
top-organization share
Programs by Stage
Early Phase 11 · 50%
Phase 1/21 · 50%
Trial / Program Status
Discontinued1 · 50%
Unknown1 · 50%
Modality Breakdown
Biologic2 · 100%
Program Types
Therapeutic2 · 100%
Top Organizations
Institution-led study1 · 50%
Investigator-sponsored study (Stanley Cohen, MD)1 · 50%
Population Tags
adult2 · 100%
autoimmune-inner-ear-disease2 · 100%
bilateral1 · 50%
older-adult1 · 50%
progressive1 · 50%
sensorineural-hearing-loss1 · 50%
steroid-dependent1 · 50%
Strong-Evidence Programs
0 recordsNo strong-evidence records yet for this indication.
Checked Records With Caveats
2 recordsIntratympanic golimumab for autoimmune inner ear diseaseStatus caveat
Sponsor / Institution: Institution-led study · Phase 1/2 · Discontinued
BiologicPhase 1/2Discontinued82% confidence
Investigator-sponsored rilonacept study for autoimmune neurosensory hearing lossStatus caveat
Sponsor / Institution: Investigator-sponsored study (Stanley Cohen, MD) · Early Phase 1 · Unknown
BiologicEarly Phase 1Unknown78% confidence